IPH4102
Phase 2Active 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, T-Cell
Conditions
Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
Trial Timeline
May 22, 2019 → Jan 31, 2026
NCT ID
NCT03902184About IPH4102
IPH4102 is a phase 2 stage product being developed by Innate Pharma for Lymphoma, T-Cell. The current trial status is active. This product is registered under clinical trial identifier NCT03902184. Target conditions include Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03902184 | Phase 2 | Active |
| NCT02593045 | Phase 1 | Completed |
Competing Products
20 competing products in Lymphoma, T-Cell